SCHEMBL3966950

SCHEMBL3966950

Cc1nc2ccc(N3CCCCC3)cc2c(-c2ccc(F)cc2)c1C(C)Oc1cccc(N(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
IDO2 Q6ZQW0 1/20 0.35
FGFR1 P11362 2/20 0.35
MAPT P10636 4/20 0.33
FAAH O00519 1/20 0.33
KDM4E B2RXH2 2/20 0.32
PSIP1 O75475 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32
KMT2A Q03164 1/20 0.32
LMNA P02545 1/20 0.32
KIT P10721 1/20 0.32
SMO Q99835 1/20 0.32
GRM5 P41594 1/20 0.32
HRH4 Q9H3N8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13881922 0.89 FGFR1 (0.38) IDO1TDO2IDO2FGFR1MAPT
SCHEMBL3969725 0.86 SOS1 (0.36) IDO1TDO2IDO2FGFR1MAPT
SCHEMBL4137225 0.85 F10 (0.41) IDO1TDO2IDO2MAPTFAAH
SCHEMBL4143703 0.85 FGFR1 (0.39) IDO1TDO2IDO2FGFR1MAPT
SCHEMBL4139178 0.85 APP (0.41) IDO1TDO2IDO2FGFR1MAPT
SCHEMBL4071227 0.84 IDO1 (0.40) IDO1TDO2IDO2FGFR1MAPT
SCHEMBL3971049 0.84 FGFR1 (0.41) IDO1TDO2IDO2FGFR1KDM4E
SCHEMBL13881532 0.84 IDO1 (0.38) IDO1TDO2IDO2FGFR1MAPT
SCHEMBL3970650 0.82 ELOVL1 (0.36) IDO1TDO2IDO2MAPTMEN1
SCHEMBL4075958 0.82 KDM4E (0.38) IDO1TDO2IDO2FGFR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009041904-A1 QUINOLINE COMPOUNDS HAVING AN ACTIVITY AGAINST THE GABAB RECEPTOR ASTRAZENECA AB (SE) 2009-04-02 WO claimed
US-20090088441-A1 Quinoline Compounds ASTRAZENECA AB (SE) 2009-04-02 US claimed
WO-2009041904-A1 QUINOLINE COMPOUNDS HAVING AN ACTIVITY AGAINST THE GABAB RECEPTOR ASTRAZENECA AB (SE) 2009-04-02 WO disclosed
US-20090088441-A1 Quinoline Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed
US-20090088441-A1 Quinoline Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed
US-20090088441-A1 Quinoline Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088441-A1 Quinoline Compounds GABRB1, HRH2, GABRA5 IDO1 996/4885TDO2 2448/4885IDO2 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.